Loading clinical trials...

Phase 3 Clinical Trial of Teriparatide in Japan | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Phase 3 Clinical Trial of Teriparatide in Japan

Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis

NCT00433160•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of teriparatide based on measurements of bone mineral density at lumbar spine

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Japanese patients diagnosed with osteoporosis
•Aged 55 or older
•Patients who are at high risk for fracture

Exclusion Criteria

•History of metabolic bone disorders other than primary osteoporosis
•History of malignant neoplasm in the 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated.
•Severe or chronically disabling conditions other than osteoporosis

Locations (16)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Aichi, Japan

Fukuoka, Japan

Hokkaido, Japan

Hyōgo, Japan

Kagoshima, Japan

Kanagawa, Japan

Nagano, Japan

Nagasaki, Japan

Numakunai, Japan

Osaka, Japan

Key Dates

Start Date

January 1, 2007

Primary Completion Date

September 1, 2008

Completion Date

September 1, 2009

Last Updated

September 21, 2010

Enrollment

207

ACTUAL participants

Conditions

Osteoporosis

Interventions

Teriparatide

DRUG

Placebo

DRUG

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

NCT06731608

OsteoporosisLower Limb Fracture

View study

RECRUITING

Smart Wearable Device (gaitQ): Walk Better Project

NCT05913219

Parkinson DiseaseStroke+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 21, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase 3 Clinical Trial of Teriparatide in Japan

Inclusion Criteria

Exclusion Criteria

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Smart Wearable Device (gaitQ): Walk Better Project

Step-down Therapy After Long-term Osteoporosis Treatment

Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning

Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship

Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device